Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. Multiple myeloma (MM) is the third most...Continue Reading
The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or relapsed/refractory multiple...Continue Reading
CURE® recently invited patients, survivors, caregivers, advocates and health care professionals to attend its first-ever live webinar, “Hear from the...Continue Reading
Every quarter we’ll post news and information in our myeloma newsletter. If you would like to join the community of patients and caregivers receiving this subscribe below.
